Investigating Safety, Tolerability and Pharmakinetics When Giving Single and Fractionated Doses of AZD3241 to Healthy Volunteers

Inclusion Criteria: * Provision of informed consent * Body Mass Index (BMI) 19 to 30 kg/m2 inclusive * Clinically normal physical findings, including BP, pulse rate, ECG and laboratory findings, as judged by the investigator Exclusion Criteria: * Clinically significant illness within the 2 weeks prior to the administration of the investigational product * Heart rate (resting, recumbent) \<50 bmp or \>85 bmp * History of severe allergy/hypersensitivity or ongoing allergy/hypersensitivity as judged by the investigator